Minerva Neurosciences | NERV - Loan Capital


Minerva Neurosciences reported $0 in Loan Capital for its fiscal quarter ending in September of 2024.





Loan Capital Change Date
Acadia Pharmaceuticals USD 0 0 Mar/2025
Adma Biologics USD 193.58M 124.25M Mar/2026
ALKERMES USD 1.48B 1.2B Mar/2026
Alterity Therapeutics Limited AUD 43.68K 59.53K Dec/2025
AstraZeneca USD 25.96B 177M Mar/2026
BioCryst Pharmaceuticals USD 395.2M 33.48M Mar/2026
Bristol-Myers Squibb USD 42.15B 698M Mar/2026
Cipla INR 3.82B 840.2M Mar/2026
Clal Biotechnology ILS 25.96M 18.48M Dec/2023
Compugen USD 0 0 Dec/2024
CSL USD 10.42B 273M Dec/2025
Eli Lilly USD 39.37B 1.5B Mar/2026
Esperion Therapeutics USD 457.65M 9.5M Dec/2025
GlaxoSmithKline GBP 14.01B 696M Mar/2026
Grifols EUR 9.95B 722.93M Dec/2025
Halozyme Therapeutics USD 1.94B 206.73M Mar/2026
Ionis Pharmaceuticals USD 1.91B 9M Mar/2026
J&J USD 37.53B 1.91B Mar/2026
Merck USD 46.67B 77M Mar/2026
Minerva Neurosciences USD 0 86.58M Sep/2024
Neurocrine Biosciences USD 169.5M 500K Mar/2023
Novartis USD 37.45B 7.86B Mar/2026
Novavax USD 246.3M 200K Dec/2025
Pfizer USD 60.57B 1.08B Mar/2026
Roche Holding CHF 27.43B 966M Dec/2025
Sanofi EUR 13.84B 1.88B Mar/2026
Takeda JPY 4.37T 99.51B Mar/2026
Vanda Pharmaceuticals USD 3.15M 3.15M Dec/2024